Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 13;11(1):2099642. doi: 10.1080/2162402X.2022.2099642

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — AlloDCs boost the therapeutic efficacy of αCTLA-4 antibody and the effect is dependent on T cells. (a) Schematic illustration of the experiment outline. (b) Tumor size of individual mice and (c) mouse survival (Kaplan-Meier curve) after different treatments (n = 10 per treatment group). (d-f) Seven tumor-free cured mice from the αCTLA-4/AlloDC and control group mice were s.c injected CT-26 tumor cells. The average tumor size (d), individual mice (e), and mouse survival were presented (PBS: n = 10, Rechallenge: n = 7). (g) Treatment schedule of the CD8⁺ and CD4⁺ T-cell depletion experiment. (h) Tumor size of individual mice and (i) mouse survival (Kaplan-Meier curve) after treatments (n = 6 per treatment group). The average tumor size from the rechallenge was compared by two-way ANOVA with Tukey correction (***, P < .001). All survival curves were compared using the log-rank test. (*: P < .05, **: P < .01, ****: P < .0001).